Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AC Platelet aggregation inhibitors excl. heparin
B01AC27 Selexipag
D09994 Selexipag (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Pulmonary Antihypertensives
Prostacyclin Receptor Agonist
Selexipag
D09994 Selexipag (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
219 Miscellaneous
2190 Miscellaneous
D09994 Selexipag (JAN/USAN/INN)
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01712 Antiplatelet agent
D09994 Selexipag
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
D09994 Selexipag
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D09994 Selexipag
DG02924 UGT substrate
DG03184 UGT1A3 substrate
D09994 Selexipag
DG03190 UGT2B7 substrate
D09994 Selexipag
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Prostacyclin
PTGIR
D09994 Selexipag (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09994
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09994
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09994
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09994
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09994